Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect Study of TAK-935 in Healthy Subjects
NCT02906813Phase 1Completed
- Sponsor
- Takeda
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of soticlestat in epilepsy (3 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration for TAK-935 up to 48 hours, Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-935 up to 48 hours and 1 more. Started Sep 2016; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02906813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906813.